2024
Noninvasive assessment of the lung inflammation-fibrosis axis by targeted imaging of CMKLR1
Mannes P, Adams T, Farsijani S, Barnes C, Latoche J, Day K, Nedrow J, Ahangari F, Kaminski N, Lee J, Tavakoli S. Noninvasive assessment of the lung inflammation-fibrosis axis by targeted imaging of CMKLR1. Science Advances 2024, 10: eadm9817. PMID: 38896611, PMCID: PMC11186491, DOI: 10.1126/sciadv.adm9817.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisFibrotic lung diseaseRisk stratificationMurine modelLung fibrosisLung diseaseModel of bleomycin-induced lung fibrosisBleomycin-induced lung fibrosisImaging biomarkersMurine model of bleomycin-induced lung fibrosisBronchoalveolar lavage cellsMonocyte-derived macrophagesPositron emission tomographyInflammatory endotypesPulmonary fibrosisLavage cellsPoor survivalNoninvasive assessmentTherapeutic monitoringEmission tomographyCMKLR1FibrosisClinical trajectoryLungLung regions
2016
SH2 Domain–Containing Phosphatase-2 Is a Novel Antifibrotic Regulator in Pulmonary Fibrosis
Tzouvelekis A, Yu G, Lino Cardenas CL, Herazo-Maya JD, Wang R, Woolard T, Zhang Y, Sakamoto K, Lee H, Yi JS, DeIuliis G, Xylourgidis N, Ahangari F, Lee PJ, Aidinis V, Herzog EL, Homer R, Bennett AM, Kaminski N. SH2 Domain–Containing Phosphatase-2 Is a Novel Antifibrotic Regulator in Pulmonary Fibrosis. American Journal Of Respiratory And Critical Care Medicine 2016, 195: 500-514. PMID: 27736153, PMCID: PMC5378419, DOI: 10.1164/rccm.201602-0329oc.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisPulmonary fibrosisProfibrotic stimuliLung fibroblastsChronic fatal lung diseaseMyofibroblast differentiationPrimary human lung fibroblastsFatal lung diseaseNovel therapeutic strategiesVivo therapeutic effectPotential therapeutic usefulnessHuman lung fibroblastsMouse lung fibroblastsDismal prognosisFibroblastic fociLung fibrosisLung diseaseBleomycin modelTherapeutic effectTherapeutic usefulnessTherapeutic strategiesTherapeutic targetTransgenic miceFibrosisSHP2 overexpression
2011
Studies of Vascular Endothelial Growth Factor in Asthma and Chronic Obstructive Pulmonary Disease
Lee CG, Ma B, Takyar S, Ahangari F, DelaCruz C, He CH, Elias JA. Studies of Vascular Endothelial Growth Factor in Asthma and Chronic Obstructive Pulmonary Disease. Annals Of The American Thoracic Society 2011, 8: 512-515. PMID: 22052929, PMCID: PMC3359071, DOI: 10.1513/pats.201102-018mw.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAsthmaDisease Models, AnimalHumansInflammationMicePulmonary Disease, Chronic ObstructiveVascular Endothelial Growth Factor AConceptsVascular endothelial growth factorRIG-like helicaseTh2 inflammationEndothelial growth factorImmune pathwaysVirus-induced COPD exacerbationsChronic obstructive pulmonary diseaseViral pathogen-associated molecular patternsRole of VEGFGrowth factorDendritic cell activationObstructive pulmonary diseaseAbrogation of VEGFInnate immune pathwaysUseful therapeutic strategyVEGF receptor blockadePathogen-associated molecular patternsTissue responseCOPD exacerbationsMucus metaplasiaEosinophilic inflammationReceptor blockadePulmonary diseaseSubepithelial fibrosisCytokine elaboration